AlphaValue Corporate Services

AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients.  The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.

Egor Sonin
  • Egor Sonin

Reassessing Cementir's Turkish Positioning

Reassessing Cementir's Turkish Positioning SIGNIFICANT NEWS Cementir sold its small Kars plant in northeastern Turkey for €51m (13x EBITDA). It is a minor move, representing less than 2% of group revenue and EBITDA. With just 0.6Mt capacity (vs. 5.4Mt in Turkey), Kars was a non-core, stand-alone asset outside Cementir’s integrated operations in western and central Turkey. However, the disposal aligns with Cementir’s strategy to streamline its footprint, free up capital, and focus on higher-gro...

Fabrice Farigoule
  • Fabrice Farigoule

Another capital increase in the pipe…

Another capital increase in the pipe… FINANCING ISSUE Crossject announced the preparation for a capital increase of approximately €5m, intended to meet the group’s needs until the Emergency Use Authorization is obtained. This amount could rise to €5.8m if the extension clause is exercised. This capital increase will provide management with flexibility for commercial and production activities related to this approval. FACT Crossject announced it is preparing a capital increase (beginning of ...

Egor Sonin
  • Egor Sonin

Cementir delivers stable Q1 amid margin pressure

Cementir delivers stable Q1 amid margin pressure EARNINGS/SALES RELEASES Cementir Holding’s first quarter of 2025 did not deliver any grand surprises – positive or negative. However, a flat EBITDA hid contrasting Baltic gains and a bout of Turkish weakness, as well as the usual FX complexities. Cash flow resilience must be saluted. FACT Revenue: €368.1m (vs €368.3m in Q1 2024) EBITDA: €66.4m (vs €66.5m in Q1 2024) Profit before tax (PBT): €30.3m (vs €58.7m in Q1 2024) Outlook for the full y...

Fabrice Farigoule
  • Fabrice Farigoule

Back to life?

Back to life? EARNINGS/SALES RELEASES CROSSJECT has provided an update on the EUA filing for Zepizure. Management has confirmed the filing will occur in June 2025, as previously indicated, demonstrating adherence to their timeline. This development is likely to enhance investor confidence, which had recently declined. Consequently, the market has reacted positively, although the successful launch of Zeneo is not yet fully reflected in the share price. Our target price remains unchanged at €6.7...

Alexandre DESPREZ
  • Alexandre DESPREZ

EPS cut (2024: from € -0.59 to -0.68, 2025: from € -0.09 to -0.09) (Dr...

EPS CHANGE CHANGE IN EPS 2025 : € (0.09) vs (0.09) ns 2026 : € 0.05 vs 0.06 -16.7% Our EPS for 2024 was impacted by the lower number of shares than expected (20.1m vs 20.5m) as the effective timing of the last capital raising announced in December 2024, came later than expected. Our EPS for 2026 was only marginally changed following the release of the annual report with full figures, which marginally impacted our estimates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch